Childhood Cancer Data Initiative (CCDI) Adds New Pediatric Malignancy Data
Are you looking for molecular characterization data derived from racial and ethnically diverse child cancer patients? If so, the recently released data from the Childhood Cancer Data Initiative (CCDI) could help you in your research.
Accessing the Data
The pediatric cancer data are stored in the NCI Cancer Research Data Commons’ Cancer Data Service. However, to access the data, you’ll need to request authorized access via the database of Genotypes and Phenotypes (dbGaP).
See the following CGC help documents for details:
Once you have access, you can then analyze the data through the Seven Bridges’ Cancer Genomics Cloud (CGC), an NCI-funded cloud resource.
About the Data
The molecular characterization data, collected from 1,039 patients, comes from the OncoKids cancer panel—a next generation sequencing assay and the flagship oncology assay of Children’s Hospital Los Angeles (CHLA).
The OncoKids assay:
- detects DNA mutations and amplification in almost 200 oncogenes and tumor suppressor genes.
- detects 1,700 disease-associated gene fusions at the RNA level.
The data set comes from the University of Southern California (USC) study. It includes data curated with clinical, treatment, and outcome characterization. Norris Comprehensive Cancer Center investigators from Population and Public Health Sciences at Keck School of Medicine led the study in collaboration with Center for Personalized Medicine at CHLA.
Dr. Amie Eunah Hwang, the principal investigator for the USC study and assistant professor of Clinical Population and Public Health Sciences at the Keck School of Medicine of USC, says, “For childhood cancer research where racial and ethnic diversity is understudied, this data set adds unique research value to the CCDI Data Ecosystem.”
“This is one of the largest clinical cohorts of pediatric cancer patients from under-represented populations with hematologic malignancies, brain tumors, and solid tumors to be profiled with a single comprehensive DNA- and RNA-based platform” said Dr. Jaclyn Biegel, director of the Center for Personalized Medicine at CHLA. “We are happy to contribute to the CCDI efforts in using this data to improve outcomes for our most vulnerable patients.”
You can email CCDI for help and questions.